Sartorius AG
General ticker "SUVPF" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $16.2B (TTM average)
Sartorius AG follows the US Stock Market performance with the rate: 34.9%.
Estimated limits based on current volatility of 0.2%: low 300.66$, high 301.86$
Factors to consider:
- Company pays dividends (annually): last record date 2025-03-31, amount 0.87$ (Y0.29%)
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [168.35$, 309.42$]
- 2025-12-31 to 2026-12-31 estimated range: [168.67$, 309.70$]
Financial Metrics affecting the SUVPF estimates:
- Negative: with PPE of 125.5 at the end of fiscal year the price was very high
- Positive: 7.86 < Operating profit margin, % of 12.93
- Positive: 18.93 < Shareholder equity ratio, % of 27.37 <= 41.86
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of 0.82
- Positive: -8.75 < Industry operating profit margin (median), % of -7.19
Short-term SUVPF quotes
Long-term SUVPF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €4,174.70MM | €3,395.70MM | €3,380.70MM |
| Operating Expenses | €3,038.80MM | €2,852.50MM | €2,943.50MM |
| Operating Income | €1,135.90MM | €543.20MM | €437.20MM |
| Non-Operating Income | €45.80MM | €-157.30MM | €-250.40MM |
| Interest Expense | €35.20MM | €144.90MM | €212.63MM |
| R&D Expense | €177.80MM | €170.80MM | €196.80MM |
| Income(Loss) | €1,181.70MM | €385.90MM | €186.80MM |
| Taxes | €268.60MM | €95.90MM | €49.40MM |
| Profit(Loss)* | €678.10MM | €205.20MM | €84.00MM |
| Stockholders Equity | €1,989.80MM | €2,067.30MM | €2,764.80MM |
| Inventory | €1,179.10MM | €1,036.70MM | €788.50MM |
| Assets | €6,977.70MM | €9,755.30MM | €10,103.00MM |
| Operating Cash Flow | €734.20MM | €853.60MM | €976.20MM |
| Capital expenditure | €522.60MM | €559.70MM | €409.90MM |
| Investing Cash Flow | €-1,129.90MM | €-2,823.30MM | €-425.80MM |
| Financing Cash Flow | €209.90MM | €2,165.70MM | €-128.30MM |
| Earnings Per Share** | €9.91 | €3.00 | €1.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.